Tag: #weightlossdrugs

GLP-1 Receptor Agonists Found Effective for Weight Loss Among Adults Without Diabetes

Since there is a lack of head-to-head trials on these agents, future research should explore their comparative efficacy (e.g. semaglutide vs. tirzepatide vs. retatrutide).

WeightControl.com Interview with:

Areesha Moiz BSc
Centre of Clinical Epidemiology, Lady Davis Institute
Jewish General Hospital, and Division of Experimental Medicine
McGill University, Montreal, Quebec, Canada
Division of Experimental Medicine
McGill University

WeightControl.com:  What is the background for this study? 

Response: GLP-1 receptor agonists have been used for type 2 diabetes management for almost two decades. Trials conducted in this patient population also showed some weight loss effects, leading to them being investigated in patients with overweight or obesity and without diabetes. With all the recent buzz around Ozempic (semaglutide) these past few years, we were interested in seeing what other agents in this class of drugs were out there, how they performed for weight loss, and how safe they were. 

Pages: Page 1, Page 2

EASD: Analysis Finds More Weight Loss (and side effects) with Tirzepatide in Type 2 Diabetes

Our analysis can help healthcare professionals make informed choices for managing type 2 diabetes, especially for those patients for whom weight loss is an important goal. However, like any medication, it’s crucial to consider the entire profile of tirzepatide, including side effects.

WeightControl.com Interview with:

Dr Thomas Karagiannis MD
Aristotle University of Thessaloniki
Thessaloniki, Greece

WeightControl.com:  What is the background for this study? What are the main findings?

Response: Previous individual studies have shown that both subcutaneous semaglutide and tirzepatide are very effective in managing blood sugar and reducing body weight in people with type 2 diabetes. However, direct comparisons between these medications have been limited.

In our study, we used a technique called a network meta-analysis to indirectly compare the two. This method allowed us to derive results by examining other trials that compared either of the drugs with placebo or another treatment.

Our findings indicated that tirzepatide had a stronger effect than semaglutide in controlling blood sugar and aiding weight loss. For example, those on the highest dose of tirzepatide lost, on average, 5.7 kg more than those on the highest dose of semaglutide. But, it’s worth mentioning that some side effects, especially related to the digestive system, were slightly more common with the high dose of tirzepatide.

Continue reading “EASD: Analysis Finds More Weight Loss (and side effects) with Tirzepatide in Type 2 Diabetes”